Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors
Autor: | Darnell, J C, Albert, M L, Darnell, R B |
---|---|
Přispěvatelé: | Laboratory of Molecular Neuro-oncology, Howard Hughes Medical Institute (HHMI)-Rockefeller University [New York], Vougny, Marie-Christine |
Jazyk: | angličtina |
Rok vydání: | 2000 |
Předmět: |
Ovarian Neoplasms
MESH: Humans [SDV.IMM] Life Sciences [q-bio]/Immunology Immune Sera Blotting Western MESH: Antigens Neoplasm Breast Neoplasms Paraneoplastic Cerebellar Degeneration Up-Regulation DNA-Binding Proteins MESH: Paraneoplastic Cerebellar Degeneration Purkinje Cells MESH: Ovarian Neoplasms MESH: Purkinje Cells Antigens Neoplasm MESH: Up-Regulation Humans MESH: Blotting Western MESH: Immune Sera [SDV.IMM]Life Sciences [q-bio]/Immunology Female MESH: Female MESH: Breast Neoplasms MESH: DNA-Binding Proteins |
Zdroj: | Cancer Research Cancer Research, American Association for Cancer Research, 2000, pp.2136-9 |
ISSN: | 0008-5472 1538-7445 |
Popis: | International audience; The paraneoplastic neurological disorders provide perhaps the best known example of naturally occurring tumor immunity in humans. For example, patients with paraneoplastic cerebellar degeneration (PCD) appear to suppress the growth of occult breast or ovarian tumors that express a neuronal antigen termed cdr2. PCD patients harbor cdr2-specific CTLs in their peripheral blood, and these cells are likely mediators of the tumor suppression. Whereas cdr2 therefore appears to be the target of an effective immune response in patients with PCD, the general relevance to cancer patients has been unclear, due in part to reports indicating that cdr2 is not expressed in tumors obtained from neurologically normal patients. We have reexamined this question, and we find that cdr2 is widely expressed in such tumors, indicating that cdr2 is in fact an important tumor antigen in the general population of breast and ovarian cancer patients. |
Databáze: | OpenAIRE |
Externí odkaz: |